Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study


Introduction: This paper reports the results of a post marketing clinical study that tested the antiviral properties of Gene-Eden-VIRTM. Specifically, the clinical study tested the effect of Gene-Eden-VIR on the severity, duration, and frequency of symptoms reported by individuals infected with various viruses. The viruses included the Human Papillomavirus (HPV), Herpes Simplex Virus (HSV), Epstein Barr Virus (EBV), Human Cytomegalovirus (HCMV) and Hepatitis C Virus (HCV). The symptoms included abnormal Pap smear, low and high grade cervical dysplasia, warts, blisters, cold sores, hives, skin tabs, panic attacks, depression, kidney problems, sleeping problems, liver problems, fever, fatigue, sore throat, swollen lymph nodes, diarrhea, and weight loss. Treatment: A capsule of Gene-Eden-VIR includes five natural ingredients: 100 mg of quercetin, 150 mg of green tea extract, 50 mg of a cinnamon extract, 25 mg of a licorice extract, and 100 mcg of selenium. The dosage was 1, 2, 3, or 4 capsules per day. The duration of treatment was 2 to 54 weeks. Population: The study population consisted of 60 infected individuals, ages 20 to 66. Results: The participants reported no side effects after taking Gene-Eden-VIR. Seventy three percent of the individuals treated with Gene-Eden-VIR reported a decrease in their symptoms. Specifically, they reported a decrease in the severity (p = 0.006, n = 45), duration (p = 0.009, n = 34), and frequency of their symptoms (p < 0.001, n = 31). Following treatment, the participants also reported an increase in their physical abilities (p < 0.001, n = 47), energy levels (p < 0.001, n = 54), mental abilities (p < 0.001, n = 44), and general health (p < 0.001, n = 46). The results showed that Gene-Eden-VIR has a duration effect (p = 0.044, n = 32), that is, those treated for a longer time reported a larger decrease in their symptoms. The results showed no interviewer bias, no selection bias, and a surprising response shift. The results also showed that Gene-Eden-VIR has therapeutic consistency under varying manufacturing conditions. Conclusions: This post marketing clinical study showed that Gene-Eden-VIR is a safe and effective antiviral treatment. Specifically, the clinical study showed that Gene-Eden-VIR is a safe and effective treatment against the Human Papillomavirus (HPV), Herpes Simplex Virus (HSV), Epstein Barr Virus (EBV), Human Cytomegalovirus (HCMV), and Hepatitis C Virus (HCV). Therefore, health care practitioners should recommend Gene-Eden-VIR as a safe and effective antiviral treatment against these viruses.

Share and Cite:

H. Polansky and E. Itzkovitz, "Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study," Pharmacology & Pharmacy, Vol. 4 No. 6A, 2013, pp. 1-8. doi: 10.4236/pp.2013.46A001.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] M. A. Stanley, “Genital Human Papillomavirus Infections: Current and Prospective Therapies,” Journal of General Virology, Vol. 93, No. 4, 2012, pp. 681-691. doi:10.1099/vir.0.039677-0
[2] E. Gershburg and J. S. Pagano, “Epstein-Barr Virus Infections: Prospects for Treatment,” Journal of Antimicrobial Chemotherapy, Vol. 56, No. 2, 2005, pp. 277-281. doi:10.1093/jac/dki240
[3] L. A. Jensen, J. D. Hoehns and C. L. Squires, “Oral Antivirals for the Acute Treatment of Recurrent Herpes Labialis,” Annals of Pharmacotherapy, Vol. 38, No. 4, 2004, pp. 705-709. doi:10.1345/aph.1D285
[4] G. Andrei, E. De Clercq and R. Snoeck, “Novel Inhibitors of Human CMV,” Current Opinion in Investigational Drugs, Vol. 9, No. 2, 2008, pp. 132-145.
[5] J. M. Pawlotsky, “New Antiviral Agents for Hepatitis C,” F1000 Biology Reports, Vol. 4, No. 5, 2012.
[6] US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), “Guidance for Industry. Botanical Drug Products,” 2004.
[7] D. M. Almog and E. M. Heisler, “Computer Intuition: Guiding Scientific Research in Imaging and Oral Implantology,” Journal of Dental Research, Vol. 76, No. 10, 1997, pp. 1684-1688. doi:10.1177/00220345970760101001
[8] A. Singal, S. Kaur, N. Tirkey and K. Chopra, “Green Tea Extract and Catechin Ameliorate Chronic Fatigue-Induced Oxidative Stress in Mice,” Journal of Medicinal Food, Vol. 8, No. 1, 2005, pp. 47-52. doi:10.1089/jmf.2005.8.47
[9] S. Y. Lyu, J. Y. Rhim and W. B. Park, “Antiherpetic Activities of Flavonoids against Herpes Simplex Virus Type 1 (HSV-1) and Type 2 (HSV-2) in Vitro,” Archives of Pharmacal Research, Vol. 28, No. 11, 2005, pp. 1293-1301. doi:10.1007/BF02978215
[10] L. K. Chang, T. T. Wei and Y. F. Chiu, “Inhibition of Epstein-Barr Virus Lytic Cycle by (-)-Epigallocatechin Gallate,” Biochemical and Biophysical Research Communications, Vol. 301, No. 4, 2003, pp. 1062-1068. doi:10.1016/S0006-291X(03)00067-6
[11] L. C. Lin, Y. C. Kuo and C. J. Chou, “Anti-Herpes Simplex Virus Type-1 Flavonoids and a New Flavanone from the Root of Limonium sinense,” Planta Medica, Vol. 66, No. 4, 2000, pp. 333-336. doi:10.1055/s-2000-8540
[12] Y. Iwase, Y. Takemura, M. Ju-ichi, et al., “Inhibitory Effect of Flavonoid Derivatives on Epstein-Barr Virus Activation and Two-Stage Carcinogenesis of Skin Tumors,” Cancer Letters, Vol. 173, No. 2, 2001, pp. 105-109. doi:10.1016/S0304-3835(01)00615-2
[13] B. Ozcelik, I. Orhan and G. Toker, “Antiviral and Antimicrobial Assessment of Some Selected Flavonoids,” Zeitschrift für Naturforschung C: A Journal of Biosciences, Vol. 61, No. 9-10, 2006, pp. 632-638.
[14] A. Arena, G. Bisignano and B. Pavone, “Antiviral and Immunomodulatory Effect of a Lyophilized Extract of Capparis spinosa L. Buds,” Phytotherapy Research, Vol. 22, No. 3, 2008, pp. 313-317. doi:10.1002/ptr.2313
[15] C. Fiore, M. Eisenhut and R. Krausse, “J Antiviral Effects of Glycyrrhiza Species,” Phytotherapy Research, Vol. 22, No. 2, 2008, pp. 141-148. doi:10.1002/ptr.2295
[16] G. J. Kapadia, M. A. Azuine and H. Tokuda, “Inhibitory Effect of Herbal Remedies on 12-O-tetradecanoylphorbol-13-Acetate-Promoted Epstein-Barr Virus Early Antigen Activation,” Phytotherapy Research, Vol. 45, No. 3, 2002, pp. 213-220. doi:10.1006/phrs.2001.0936
[17] J. C. Lin, “Mechanism of Action of Glycyrrhizic Acid in Inhibition of Epstein-Barr Virus Replication in Vitro,” Antiviral Research, Vol. 59, No. 1, 2003, pp. 41-47. doi:10.1016/S0166-3542(03)00030-5
[18] T. Sekizawa, K. Yanagi and Y. Itoyama, “Glycyrrhizin Increases Survival of Mice with Herpes Simplex Encephalitis,” Acta Virologica, Vol. 45, No. 1, 2001, pp. 51-54.
[19] F. Benencia and M. C. Courreges, “In Vitro and in Vivo Activity of Eugenol on Human Herpesvirus,” Phytotherapy Research, Vol. 14, No. 7, 2000, pp. 495-500. doi:10.1002/1099-1573(200011)14:7<495::AID-PTR650>3.0.CO;2-8
[20] Y. Tragoolpua and A. Jatisatienr, “Anti-Herpes Simplex Virus Activities of Eugenia caryophyllus (Spreng.) Bullock & S. G. Harrison and Essential Oil, Eugenol,” Phytotherapy Research, Vol. 21, No. 12, pp. 1153-1158. doi:10.1002/ptr.2226
[21] Y. Orihara, H. Hamamoto, H. Kasuga, et al., “A Silkworm-Baculovirus Model for Assessing the Therapeutic Effects of Antiviral Compounds: Characterization and Application to the Isolation of Antivirals from Traditional Medicines,” Journal of General Virology, Vol. 89, No. 1, 2008, pp. 188-194. doi:10.1099/vir.0.83208-0
[22] S. W. Jian, C. E. Mei, Y. N. Liang, et al., “Influence of Selenium-Rich Rice on Transformation of Umbilical Blood B Lymphocytes by Epstein-Barr Virus and Epstein-Barr Virus Early Antigen Expression,” Ai Zheng, Vol. 22, No. 1, 2003, pp. 26-29.
[23] H, Wojtowicz, K. Kloc, I. Maliszewska, et al., “Azaanalogues of Ebselen (Selenium-Containing Agents) as Antimicrobial and Antiviral Agents: Synthesis and Properties,” Il Farmaco, Vol. 59, No. 11, 2004, pp. 863-868. doi:10.1016/j.farmac.2004.07.003
[24] G. N. Schrauzer, “Effects of Selenium and Low Levels of Lead on Mammary Tumor Development and Growth in MMTV-Infected Female Mice,” Biological Trace Element Research, Vol. 125, No. 3. 2008, pp. 268-275. doi:10.1007/s12011-008-8172-1
[25] US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), “Guidance for Industry, E 10 Choice of Control Group and Related Issues in Clinical Trials,” 2001.
[26] M. Breidert and K. Hofbauer, “Placebo: Misunderstandings and Prejudices,” Deutsches Arzteblatt International, Vol. 106, No. 46, 2009, pp. 751-755.
[27] R. J. Willke, L. B. Burke and P. Erickson, “Measuring Treatment Impact: A Review of Patient-Reported Outcomes and Other Efficacy Endpoints in Approved Product Labels,” Controlled Clinical Trials, Vol. 25, No. 6, 2004, pp. 535-552. doi:10.1016/j.cct.2004.09.003
[28] P. D. Harvey and R. S. Keefe, “Studies of Cognitive Change in Patients with Schizophrenia Following Novel Antipsychotic Treatment,” American Journal of Psychiatry, Vol. 158, No. 2, 2001, pp. 176-184. doi:10.1176/appi.ajp.158.2.176
[29] C. E. Schwartz, R. Bode, N. Repucci, et al., “The Clinical Significance of Adaptation to Changing Health: A Meta-Analysis of Response Shift,” Quality of Life Research, Vol. 15, No. 9, 2006, pp. 1533-1550. doi:10.1007/s11136-006-0025-9
[30] N. L. Frederiksen, “Diagnostic Imaging in Dental Implantology,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, Vol. 80, No. 5, 1995, pp. 540-554. doi:10.1016/S1079-2104(05)80153-2
[31] D. M. Almog, B. W. Benson, L. Wolfgang, et al., “Computerized Tomography-Based Imaging and Surgical Guidance in Oral Implantology,” Journal of Oral Implantology, Vol. 32, Vol. 1, 2006, pp. 14-18.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.